Fluoxetine selectively induces p53-independent apoptosis in human colorectal cancer cells

Article


Marcinkute, M., Afshin Javid, S., Fatokun, A. A. and Javid, F. A. 2019. Fluoxetine selectively induces p53-independent apoptosis in human colorectal cancer cells. European Journal of Pharmacology.
AuthorsMarcinkute, M., Afshin Javid, S., Fatokun, A. A. and Javid, F. A.
Abstract

Fluoxetine has been shown to induce anti-tumour activity. The aim of this study was to determine the effect of fluoxetine on HCT116+/+ and p53 gene-depleted HCT116-/- human colorectal cancer cells and the mechanisms, including potential p53-dependence, of its action. Fluoxetine-induced apoptosis was investigated by mitochondrial membrane potential assay, Annexin V assay, two-step cell cycle analysis using NC-3000™ system and pharmacological inhibition assays. Fluoxetine induced very selectively concentration-dependent apoptosis in human colorectal cancer cells by altering mitochondrial membrane potential and inducing translocation of phosphatidylserine to the outer membrane layer. Further evidence of the preponderance of apoptosis in fluoxetine-induced cell death is provided by the finding that the cell death was not blocked by inhibitors of parthanatos, a form of cell death that results from overactivation of the enzyme poly (ADP-ribose) polymerase (PARP) but is different from apoptosis. Data obtained indicate fluoxetine caused cell cycle event at Sub-G1 and G0/G1 phases in both cell lines. In terms of apoptosis, there is no significant difference between the responses of the two cell lines to fluoxetine.

In conclusion, fluoxetine's cytotoxicity induces mainly apoptosis and causes DNA fragmentation in human colorectal cancer cells, which seemed to be independent of the p53 protein, as no significant difference in death profiles in response to fluoxetine treatment was observed in both the p53-intact and the p53-deleted cell lines. Fluoxetine, therefore, has potential for being repurposed as a drug for the treatment of colon cancer and thus deserves further investigations in this context.

JournalEuropean Journal of Pharmacology
ISSN0014-2999
Year2019
PublisherElsevier
Accepted author manuscript
License
File Access Level
Anyone
Digital Object Identifier (DOI)doi:10.1016/j.ejphar.2019.172441
Web address (URL)https://doi.org/10.1016/j.ejphar.2019.172441
Publication dates
Online07 Jun 2019
Publication process dates
Accepted06 Jun 2019
Deposited18 Jun 2019
Copyright holder© 2019 Elsevier.
Permalink -

https://repository.uel.ac.uk/item/86v7z

Accepted author manuscript

  • 7
    total views
  • 0
    total downloads
  • 1
    views this month
  • 0
    downloads this month